Evidence map›Paper›PMID 32413187›Full record

ArticleCancer2020

Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study.

Mukta Arora, Yanjun Chen, Lindsey Hageman, Jessica Wu, Wendy Landier, Liton Francisco, Michelle Kung, Emily Ness, Alysia Bosworth, Merve Pamukcuoglu and 4 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Mukta AroraDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0001-9362-0556
Yanjun ChenInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Lindsey HagemanInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Jessica WuInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Wendy LandierInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Liton FranciscoInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Michelle KungInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Emily NessInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Alysia BosworthDepartment of Population Sciences, City of Hope National Medical Center, Duarte, California, USA.
Merve PamukcuogluDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Daniel J WeisdorfDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Stephen J FormanDepartment of Population Sciences, City of Hope National Medical Center, Duarte, California, USA.
Saro H ArmenianDepartment of Population Sciences, City of Hope National Medical Center, Duarte, California, USA.ORCID 0000-0003-2604-8603
Smita BhatiaInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-7755-5683
University of Alabama at Birmingham · USCity Of Hope National Medical Center · USUniversity of Minnesota · US

Funding

BMT Survivor Study-2 (BMTSS-2)U01CA213140 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATIA, SMITA · 2019 to 2023
$6.8M
BONE MARROW TRANSPLANT (BMT) SURVIVORS STUDYR01CA078938 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI BHATIA, SMITA · 2000 to 2003
$1.6M
Leukemia and Lymphoma Society R6502-16 (SB)NCI NIH HHS R01 CA078938NCI NIH HHS U01 CA213140
6 · The paper itself

Abstract

backgroundAutologous blood or bone marrow transplantation (aBMT) is considered the standard of care for patients with multiple myeloma (MM). Significantly improved survival necessitates an understanding of the morbidity burden borne by the growing survivor population.

methodsThe authors evaluated severe and/or life-threatening chronic health conditions (CHCs) and subsequent neoplasms (SNs) in patients with MM who were treated with aBMT using the Bone Marrow Transplant Survivor Study. A total of 630 study participants had undergone aBMT for MM at 1 of 3 BMT centers, had survived ≥2 years after aBMT, and were aged ≥18 years at the time of survey completion. Survivors of aBMT identified 289 nearest-age siblings to constitute an unaffected comparison group. Scoring of CHCs was based on version 5 of the National Cancer Institute Common Terminology Criteria for Adverse Events to determine severity (with grade 3 indicating serious and grade 4 indicating life-threatening).

resultsThe 10-year cumulative incidence of any grade 3 to 4 CHC among survivors of aBMT was 57.6 ± 3.2%. Survivors of MM were found to be at 40% higher odds of developing grade 3 to 4 CHCs when compared with siblings (95% confidence interval [95% CI], 1.0-1.9). Among SNs, 96% were solid tumors, yielding a 10-year cumulative incidence of 13.6% ± 2.5%. Pre-aBMT exposure to cyclophosphamide (hazard ratio [HR], 3.5; 95% CI, 1.5-8.1) and immunomodulatory drugs (HR, 3.9; 95% CI, 1.5-10.1) were associated with an increased risk of solid tumors. Melanoma (10-year cumulative incidence: 3.3% ± 1.2%) and squamous cell carcinoma (10-year cumulative incidence: 5.1% ± 1.8%), were the most common SNs. Pre-aBMT exposure to cyclophosphamide (HR, 6.02; 95% CI, 1.4-26.1) and immunomodulatory drugs (HR, 7.9; 95% CI, 0.9-68.5) was associated with an increased risk of melanoma.

conclusionsThe 10-year cumulative incidence of severe and/or life-threatening CHCs was found to approach 60% in long-term survivors of MM, with solid SNs constituting a large morbidity burden. The current study has provided evidence supporting the close monitoring of survivors to manage morbidity.

Indexed as

Cancer SurvivorsAgedAlabamaBone Marrow TransplantationCarcinoma, Squamous CellChronic DiseaseCyclophosphamideFemaleFollow-Up StudiesGraft RejectionHumansImmunosuppressive AgentsIncidenceMaleMelanomaMiddle AgedCyclophosphamideImmunosuppressive Agentsautograftshematopoietic stem cell transplantationlong-term survivorsmultiple myelomasecond neoplasms

Identifiers

PMID32413187
PMCPMC9145592
OpenAlexW3024496326

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.